ArticleThe EMBO journal2019
NLRC3 expression in dendritic cells attenuates CD4
Article in The EMBO journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- NLRC3 in septic immunosuppression: Variation in expression and mechanisms of mediating immune cell dysfunction (Review).Experimental and therapeutic medicine · 2026Review
- Article
- Role of NLRC3 in modulating inflammatory responses in neonates.BMC pediatrics · 2025Article
- Article
- RNF213 promotes Treg cell differentiation by facilitating K63-linked ubiquitination and nuclear translocation of FOXO1.Nature communications · 2024Article
- NLRC3 attenuates osteoclastogenesis by limiting TNFαJournal of molecular medicine (Berlin, Germany) · 2024Article
- cGLRs Join Their Cousins of Pattern Recognition Receptor Family to Regulate Immune Homeostasis.International journal of molecular sciences · 2024Review
- Nlrc3 signaling is indispensable for hematopoietic stem cell emergence via Notch signaling in vertebrates.Nature communications · 2024Article
- Mechanism and Application Prospects of NLRC3 Regulating cGAS-STING Pathway in Lung Cancer Immunotherapy.International journal of medical sciences · 2024Review
- CXCR1 drives the pathogenesis of EAE and ARDS via boosting dendritic cells-dependent inflammation.Cell death & disease · 2023Article
- USP1-regulated reciprocal differentiation of Th17 cells and Treg cells by deubiquitinating and stabilizing TAZ.Cellular & molecular immunology · 2023Article
- RNF157 attenuates CD4Theranostics · 2023Article
- Triptoquinone A and B exercise a therapeutic effect in systemic lupus erythematosus by regulating NLRC3.PeerJ · 2023Article
- The regulation of self-tolerance and the role of inflammasome molecules.Frontiers in immunology · 2023Review
- Role of Microgliosis and NLRP3 Inflammasome in Parkinson's Disease Pathogenesis and Therapy.Cellular and molecular neurobiology · 2022Review
- Application and prospect of targeting innate immune sensors in the treatment of autoimmune diseases.Cell & bioscience · 2022Review
- Bioinspired membrane-based nanomodulators for immunotherapy of autoimmune and infectious diseases.Acta pharmaceutica Sinica. B · 2022Review
- Negative regulator NLRC3: Its potential role and regulatory mechanism in immune response and immune-related diseases.Frontiers in immunology · 2022Review
- NOD-like receptors in asthma.Frontiers in immunology · 2022Review
- Dendritic Cell-Targeted Therapies to Treat Neurological Disorders.Molecular neurobiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
NOD-like receptor (NLR) family CARD domain containing 3 (NLRC3), an intracellular member of NLR family, is a negative regulator of inflammatory signaling pathways in innate and adaptive immune cells. Previous reports have shown that NLRC3 is expressed in dendritic cells (DCs). However, the role of NLRC3 in DC activation and immunogenicity is unclear. In the present study, we find that NLRC3 attenuates the antigen-presenting function of DCs and their ability to activate and polarize CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.